$VCYT insider trading
Over the last 12 months, Veracyte insiders reported no purchases and 37 sales totaling $21.5M across SEC Form 4 filings. 95% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $21.5M 37 events
- Events · 12m
- 37 Form 4 filings, grouped
- Insiders · 12m
- 11 distinct reporters
- 10b5-1 share
- 95% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | Febbo Phillip G.Chief Scientific & Med Officer · O | ▼ Sale | 13,110 | $43.05 | $564K | -9% | plan · 2 tranches |
| Sep 4, 2026 | Chambers RebeccaChief Financial Officer · O | ▼ Sale | 3,652 | $43.1 | $157K | -2.2% | plan · 2 tranches |
| Sep 4, 2026 | McGuire AnnieEVP, General Counsel · O | ▼ Sale | 3,254 | $43.09 | $140K | -2.4% | plan · 2 tranches |
| Sep 1, 2026 | Bhanji MunaD | ▼ Sale | 1,864 | $42.97 | $80K | -4.2% | plan |
| Jun 18, 2026 | EASTHAM KARIND | ▼ Sale | 3,729 | $52.89 | $197K | -19.8% | plan · 2 tranches |
| Jun 4, 2026 | McGuire AnnieEVP, General Counsel · O | ▼ Sale | 1,776 | $50.12 | $89K | -1.3% | plan |
| Jun 4, 2026 | McGuire AnnieEVP, General Counsel · O | ▼ Sale | 1,400 | $49.31 | $69K | -1% | plan |
| Jun 4, 2026 | Chambers RebeccaChief Financial Officer · O | ▼ Sale | 1,961 | $50.09 | $98K | -1.1% | plan |
| Jun 4, 2026 | Chambers RebeccaChief Financial Officer · O | ▼ Sale | 1,600 | $49.28 | $79K | -0.9% | plan |
| Jun 4, 2026 | Stapley MarcChief Executive Officer · O·D | ▼ Sale | 138,051 | $50.12 | $6.9M | -23.9% | plan |
| Jun 4, 2026 | Leite JohnGlobal Chief Commercial Off · O | ▼ Sale | 13,975 | $50.07 | $700K | -9.6% | plan |
| May 22, 2026 | Wygant JonathanVP, Chief Accounting Officer · O | ▼ Sale | 24,000 | $45.4 | $1.1M | -34.6% | — |
| May 6, 2026 | McGuire AnnieSVP, General Counsel · O | ▼ Sale | 10,204 | $39.02 | $398K | -6.6% | plan · 2 tranches |
| Mar 4, 2026 | Leite JohnChief Commercial Officer-CLIA · O | ▼ Sale | 5,260 | $35.19 | $185K | -4.7% | plan |
| Mar 4, 2026 | McGuire AnnieSVP, General Counsel · O | ▼ Sale | 6,658 | $35.55 | $237K | -6.6% | plan · 2 tranches |
| Mar 4, 2026 | Chambers RebeccaChief Financial Officer · O | ▼ Sale | 18,341 | $36.14 | $663K | -12.3% | plan · 2 tranches |
| Mar 4, 2026 | Stapley MarcChief Executive Officer · O·D | ▼ Sale | 45,523 | $35.97 | $1.6M | -11.3% | plan · 2 tranches |
| Mar 2, 2026 | Febbo Phillip G.Chief Scientific & Med Officer · O | ▼ Sale | 13,425 | $36.16 | $485K | -10.3% | plan |
| Dec 16, 2025 | McGuire AnnieSVP, General Counsel · O | ▼ Sale | 10,739 | $43.13 | $463K | -13.7% | plan · 2 tranches |
| Dec 5, 2025 | EASTHAM KARIND | ▼ Sale | 20,000 | $45.45 | $909K | -59.6% | plan · 3 tranches |
| Dec 4, 2025 | Leite JohnChief Commercial Officer-CLIA · O | ▼ Sale | 1,278 | $47.51 | $61K | -1.5% | plan |
| Dec 4, 2025 | McGuire AnnieSVP, General Counsel · O | ▼ Sale | 1,422 | $47.3 | $67K | -1.8% | plan · 2 tranches |
| Dec 4, 2025 | Chambers RebeccaChief Financial Officer · O | ▼ Sale | 13,278 | $46.84 | $622K | -10.8% | plan · 2 tranches |
| Dec 4, 2025 | Stapley MarcChief Executive Officer · O·D | ▼ Sale | 7,668 | $47.09 | $361K | -2.4% | plan · 2 tranches |
| Nov 25, 2025 | Leite JohnChief Commercial Officer-CLIA · O | ▼ Sale | 2,808 | $50 | $140K | -3.2% | plan |
| Nov 25, 2025 | JONES EVAN/ FAD | ▼ Sale | 1,106 | $50.25 | $56K | -3.6% | plan |
| Nov 20, 2025 | Holstein JensD | ▼ Sale | 10,000 | $42.36 | $424K | -26.9% | plan · 3 tranches |
| Nov 10, 2025 | Wygant JonathanVP, Chief Accounting Officer · O | ▼ Sale | 10,920 | $41.2 | $450K | -22% | 2 tranches |
| Nov 5, 2025 | McGuire AnnieSVP, General Counsel · O | ▼ Sale | 6,466 | $40 | $259K | -7.2% | plan |
| Nov 5, 2025 | Chambers RebeccaChief Financial Officer · O | ▼ Sale | 7,000 | $41 | $287K | -5.3% | plan |
| Nov 5, 2025 | EASTHAM KARIND | ▼ Sale | 9,674 | $40.02 | $387K | -41.6% | plan |
| Nov 5, 2025 | JONES EVAN/ FAD | ▼ Sale | 43,196 | $45.06 | $1.9M | -58.6% | plan · 6 tranches |
| Oct 6, 2025 | Febbo Phillip G.Chief Scientific & Med Officer · O | ▼ Sale | 8,349 | $36.02 | $301K | -8.3% | plan |
| Oct 1, 2025 | Leite JohnChief Commercial Officer-CLIA · O | ▼ Sale | 2,539 | $35 | $89K | -2.8% | plan |
| Oct 1, 2025 | McGuire AnnieSVP, General Counsel · O | ▼ Sale | 2,160 | $35 | $76K | -2.4% | plan |
| Oct 1, 2025 | EPSTEIN ROBERT SD | ▼ Sale | 21,473 | $35.08 | $753K | -25.6% | plan |
| Sep 19, 2025 | McGuire AnnieSVP, General Counsel · O | ▼ Sale | 2,283 | $33.69 | $77K | -2.4% | plan |
| Sep 4, 2025 | Stapley MarcChief Executive Officer · O·D | ▼ Sale | 7,667 | $30.41 | $233K | -2.2% | plan |
Every $VCYT filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Veracyte filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $VCYT feed.